Japan
REPROCELL, founded in 2003, operates at the forefront of the Biotechnology industry with a mission encapsulated by its slogan, "Better Translating Discoveries into Therapies." The company specializes in comprehensive support for stem cell research and pre-clinical drug development.
Its unique offerings include access to human tissues through BioServe, human tissue testing via Biopta, and a range of stem cell culture media and reprogramming technologies under the Stemgent banner. By leveraging expertise in bioengineered (3D) tissue models and pharmacology, REPROCELL has positioned itself as a leader in regenerative medicine and drug development tools.
The company's strategic acquisitions began with Stemgent, BioServe, and Reinnervate in 2014, followed by Biopta in 2015. Now publicly traded on Japan's JASDAQ since 2013, REPROCELL continues to expand its offerings, including a new business unit targeting clinical-grade regenerative medicine products. Most recently, a Grant investment was secured from the Maryland Stem Cell Research Fund (MSCRF) on 01 October 2025, reflecting ongoing investor confidence.
